Powered by RND
PodcastsEducaciónDNA Today: A Genetics Podcast

DNA Today: A Genetics Podcast

Kira Dineen
DNA Today: A Genetics Podcast
Último episodio

Episodios disponibles

5 de 357
  • #356 From Statehouse to Capitol Hill: A Guide to Effective Advocacy for Rare Diseases
    What does it really take to move the needle on health equity for rare diseases, especially on Capitol Hill? In this episode, we are joined by Jenifer Waldrop, Executive Director of the Rare Disease Diversity Coalition (RDDC). Under her leadership, the coalition is tackling systemic inequities across the rare disease journey, from timely diagnosis to clinical trial access, treatment development, and sustained care. With partnerships across biotech, government, and patient advocacy groups, RDDC is reshaping the policy landscape to ensure historically underrepresented communities are not left behind. Right now we are capturing Jenifer’s insider perspective on advocacy strategies, legislative progress, and how every member of the rare disease community can engage in meaningful change.  Topics Covered in This Episode: Why the Rare Disease Diversity Coalition (RDDC) was created Unique health disparities impacting rare disease patients Barriers faced by black, brown, and LGBTQ+ communities in rare disease care Collaborations between advocacy organizations and biotech leaders like Amgen Legislative efforts, including RDDC’s HEARD (H.R.1750) health equity bill with Rep. Marilyn Strickland Strategies for engaging Congress and policymakers effectively How patients and families can prepare for Capitol Hill advocacy meetings Practical advice for advocates who feel powerless but want to get involved Long-term vision for advancing equity in rare disease research, care, and policy Resources:  Rare Disease Diversity Coalition (RDDC) Website The Orphan Drug Act 1983 strongly influenced by The National Organization for Rare Disorders (NORD) H.R.1750 - HEARD Act of 2025 (Health Equity and Rare Disease Act of 2025)  The Tuskegee Syphilis Study   We Work For Health  Relevant DNA Today Episodes :  Amgen's Urea Cycle Disorder Series Part 1: #282 The Evolution of Caring for Females With OTC Deficiency Amgen's Urea Cycle Disorder Series Part 2: #323 Supporting Ongoing Urea Cycle Disorder (UCD) Care Amgen's Urea Cycle Disorder Series Part 2: #338 Social Determinants of Health and Mental Health in Urea Cycle Disorders   Connect with DNA Today: Shoutout to listener Grace Dougherty for recommending Jenifer Waldrop to be a guest on the show! Do you have someone you want to hear on DNA Today? Send a pitch to [email protected].  Get ready, genetic nerds—another brand-new episode of DNA Today drops next Friday! You can always count on us to deliver fresh content every Friday.  While you wait, why not dive into our library of over 350 episodes? Binge them all on Apple Podcasts, Spotify, our website, or wherever you love to listen—just search “DNA Today.” Prefer watching? We’ve got you covered! For the past four years, we’ve been recording episodes with video, including some filmed at the iconic NBC Universal Stamford Studios. Check them out on our YouTube channel!  DNA Today is hosted and produced by Kira Dineen, MS, LCGC, CG(ASCP)CM . Our Video Lead is Amanda Andreoli. Our Social Media Lead Liv Davidson. And our logo Graphic Designer is Ashlyn Enokian, MS, CGC.  See what else we are up to on Instagram, X (Twitter), BluSky, Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. Questions/inquiries can be sent to [email protected]
    --------  
    33:42
  • #355 How Genomics Is Transforming Rare Disease Diagnosis in Turkey
    What if we could ease the suffering of patients with undiagnosed or rare diseases? In this episode, we explore how genomics is reshaping care for some of the most medically complex patients, focusing on the rare disease landscape in Turkey. Our guests are Professor Serdar Ceylaner, a leading medical geneticist and founder of the Intergen Center for Genetics and Rare Disease Diagnosis and Research, and Alice Peng from MGI Tech, a global leader in gene sequencing innovation. Together, they offer a powerful global perspective on the challenges and solutions in rare disease diagnostics, from rapid whole genome sequencing in the NICU to affordable access in developing regions.   Alice (Yao) Peng, Sales Manager of MGI, is responsible for the Turkish Market. She has been working in the genomics field for eight years, the last five have been with MGI. Her background is in preventive medicine, and she is passionate about bringing innovative genetic solutions to customers in Turkey.    Professor Dr. Serdar Ceylaner is a medical doctor - medical geneticist who focuses on rare and undiagnosed diseases for both diagnosis and scientific studies. He is the director, partner and founder of Intergen Genetics and Rare Diseases Diagnostic and Research Center and Lokman Hekim University, Department of Medical Genetics. He holds various leadership positions including being the Vice President of the Rare and Undiagnosed Diseases Committee, of the  European Union of Medical Specialists (UEMS).  Dr. Ceylaner is the former president of the Turkish Medical Genetics Association. He was the founder of the Genetics Department of Zekai Tahir Burak Women's Health and Training Hospital between 1997 and 2017. He has focused on genetics and rare diseases and studies in this field for 30 years. He established a center for diagnosis, research and educational work in this field. Undiagnosed diseases, medical complications, and intensive care unit patients are the main research areas in recent years. He has experience in more than 250 international publications, 10 book chapters, more than 500 conferences, and more than 50 scientific projects. Topics include: The rare disease burden in Turkey and the impact of consanguinity Prevalence of dual or triple diagnoses in Turkey and the impact of tailoring treatment  Why exome and genome sequencing are replacing panel testing The diagnostic power of rapid WGS in NICUs Tools MGI offers to accelerate analysis and interpretation Making sequencing more accessible in low-resource settings The role of genomics in precision prescribing Opportunities to improve patient quality of life post-diagnosis What’s next for sequencing innovation and rare disease care Relevant Resources: DNA Today Episode #109 Shenela Lakhani on Genetic Counseling in Qatar  The Undiagnosed Diseases Network (UDN) MGI’s Sequencing Platforms Dr. Serdar Ceylander’s INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center Connect With Us Get ready, genetic nerds—another brand-new episode of DNA Today drops this Friday! You can always count on us to deliver fresh content every Friday.  While you wait, why not dive into our library of over 350 episodes? Binge them all on Apple Podcasts, Spotify, our website, or wherever you love to listen—just search “DNA Today.” Prefer watching? We’ve got you covered! For the past four years, we’ve been recording episodes with video, including some filmed at the iconic NBC Universal Stamford Studios. Check them out on our YouTube channel!  DNA Today is hosted and produced by Kira Dineen, MS, LCGC, CG(ASCP)CM. Our Video Lead is Amanda Andreoli. Our Social Media Lead is Liv Davidson. And our logo Graphic Designer is Ashlyn Enokian, MS, CGC.  See what else we are up to on Instagram, X (Twitter), BluSky, Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. Questions/inquiries can be sent to [email protected]
    --------  
    36:55
  • #354 How Pharmacogenomics is Revolutionizing Drug Prescriptions
    Why do some medications work perfectly for one person but cause side effects—or fail completely—for another? The answer often lies in our genes. Pharmacogenomic (PGx) testing analyzes how our DNA affects our response to medications, helping doctors personalize treatment, reduce adverse reactions, and improve outcomes. Joining us today are Kristy Bouvier and Kathleen O’Brien from Quest Diagnostics, both of whom have decades of experience in the field. Kristy, a product manager, brings deep expertise in pharmaceuticals, while Kathleen, a board-certified genetic counselor, specializes in pharmacogenomics and hereditary oncology. In this episode, we’ll explore: ✅ How pharmacogenomics (PGx) works and what results the test provides ✅ How PGx testing prevents adverse drug reactions and improves treatment ✅ Real-world examples of PGx in action ✅ Challenges and future trends in integrating pharmacogenomics into healthcare ✅ What patients should know before getting tested The Panel:  Kristy Bouvier started her career with Quest Diagnostics in 2014 as a Neurology Account Executive for the Boston North territory.  In this role she has over 8 years of experience in laboratory sales specializing in neurology and genetics. Currently Kristy serves as a product manager for U.S. Specialty genetics where she is responsible for the Quest genetics portfolio in rare diseases.  She currently manages the biochemical genetics, cytogenetics, pharmacogenomics, and whole exome product lines.   Kathleen O’Brien, MS, DABMG, CGC is a board-certified genetic counselor who has been with Quest Diagnostics since 2005. She previously worked in clinical genetic counseling at Stony Brook University Hospital, Winthrop University Hospital (now NYU), and the NYS Institute for Basic Research. She earned her Master of Science in Genetic Counseling from the University of Colorado Health Sciences Center and has a special interest in hereditary oncology and pharmacogenomics, actively contributing to CPIC, NSGC, and the NSGC pharmacogenetics working group.   Resources:  Quest’s New Pharmacogenomics Panel GeneReviews ClinPGx Sequence2Script The PREPARE Study Table of Pharmacogenomic Biomarkers in Drug Labeling The Clinical Pharmacogenetics Implementation Consortium (CPIC®) DNA Today Episode #324 Genetic Contraindications for Ozempic and Wegovy (GLP-1 Agonists) with Dr. Josiah Allen  Get ready, genetic nerds—another brand-new episode of DNA Today drops this Friday! You can always count on us to deliver fresh content every Friday.  While you wait, why not dive into our library of over 350 episodes? Binge them all on Apple Podcasts, Spotify, our website, or wherever you love to listen—just search “DNA Today.” Prefer watching? We’ve got you covered! For the past four years, we’ve been recording episodes with video, including some filmed at the iconic NBC Universal Stamford Studios. Check them out on our YouTube channel!  DNA Today is hosted and produced by Kira Dineen, MS, LCGC, CG(ASCP)CM . Our Video Lead is Amanda Andreoli. Our Social Media Lead is Liv Davidson. And our logo Graphic Designer is Ashlyn Enokian, MS, CGC.  See what else we are up to on Instagram, X (Twitter), BluSky, Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. Questions/inquiries can be sent to [email protected].   
    --------  
    31:43
  • #353 Advancing Telomere Research: A Breakthrough Leads to Clinical Trial
    This special episode of DNA Today was recorded live during Cocktails & Chromosomes, a celebration hosted by Team Telomere in New York City. Held at the stunning venue donated by Hogan Lovells (390 Madison Ave), the evening brought together the telomere biology disorder (TBD) community, including patients, families, clinicians, and researchers, for cocktails, connection, and powerful conversations. Two inspiring and informative guests join the episode:  Jena Robertson is the Program Administrator at Team Telomere, a patient advocate, and mother to Lorelei (“Rori”), a young girl living with a telomere biology disorder. Will Mannherz is a MD-PhD Harvard Medical School student and co-author of multiple research papers exploring TBDs and emerging therapeutic strategies. Together, Jena and Will help us understand both the personal and scientific sides of TBDs, from diagnosis to discovery. Topics Covered in This Episode Jena shares the emotional and complex diagnostic odyssey for her daughter Rori that included multiple misdiagnoses.  Rori’s final correct diagnosis of Dyskeratosis Congenita, which is a telomere biology disorder.  What it’s like parenting a child with a rare, poorly understood condition. The role of Team Telomere in providing support, resources, and hope to families worldwide. Will explains the biology of telomeres, what goes wrong in TBDs, and how thymidine may help elongate telomeres. Importance of family health history in understanding TBD disorders Insights from recent research and what early findings suggest about future treatment potential. How researchers and families are coming together to accelerate progress in this ultra-rare disease space. The upcoming clinical trial starting Fall 2025 at Boston Children’s Hospital Slight correction: In the interview Kira indicates that Team Telomere exclusively raised $1 million for the disorder, this is incorrect, there were other donors involved that all added up to $1 million including Boston’s Children’s Hospital and the Martin family. Memorable Quotes 🗨️ “We kept getting misdiagnoses... it was frustrating, but it also pushed us to keep looking until we found someone who understood telomere biology.” – Jena Robertson 🗨️ “It’s rare, but the impact is massive. Understanding telomere biology isn’t just about rare disorders—it’s about aging, cancer, and regenerative medicine.” – Will Mannherz, MD, PhD About Team Telomere Team Telomere is a New York–based nonprofit dedicated to supporting families impacted by telomere biology disorders. Through advocacy, community-building events like Cocktails & Chromosomes, and support of cutting-edge research, Team Telomere is lighting the path forward for TBD patients and their families. Learn more and get involved here.  Relevant Resources  DNA Today Episode #93 Team Telomere featuring Dr. Suneet Argwal, Katie Stevens, and Dr. Sharen Savage  A Race for Rori: The Work of Dr. Suneet Agarwal (Video played at event) Team Telomere Team Telomere’s Profile on Rori Agarwal Lab (Drs. Suneet Agarwal, Will Mannherz, et. al. TBD research)  Fall 2025 Clinical Trial: Nucleoside Therapy in Patients With Telomere Biology Disorders Dyskeratosis Congenita Information via Boston Children’s Hospital “Playing the long game: An exciting discovery in telomere disease” Boston Children’s Hospital Article Referenced Research Articles Check out these key papers Will Mannherz brought up during the episode related to telomere biology disorders and thymidine research. Many of which he is a co-author on! Domínguez-González, C., Madruga-Garrido, M., Mavillard, F., Garone, C., Aguirre-Rodríguez, F. J., Donati, M. A., Kleinsteuber, K., Martí, I., Martín-Hernández, E., Morealejo-Aycinena, J. P., Munell, F., Nascimento, A., Kalko, S. G., Sardina, M. D., Álvarez Del Vayo, C., Serrano, O., Long, Y., Tu, Y., Levin, B., Thompson, J. L. P., … Hirano, M. (2019). Deoxynucleoside Therapy for Thymidine Kinase 2-Deficient Myopathy. Annals of neurology, 86(2), 293–303. https://doi.org/10.1002/ana.25506 Mannherz, W., Agarwal, S. Thymidine nucleotide metabolism controls human telomere length. Nat Genet 55, 568–580 (2023). https://doi.org/10.1038/s41588-023-01339-5 Mannherz, W., Crompton, A., Lampl, N. et al. Metabolic constraint of human telomere length by nucleotide salvage efficiency. Nat Commun 16, 3000 (2025). https://doi.org/10.1038/s41467-025-58221-7 van der Vis, J. J., van der Smagt, J. J., Hennekam, F. A. M., Grutters, J. C., & van Moorsel, C. H. M. (2020). Pulmonary Fibrosis and a TERT Founder Mutation With a Latency Period of 300 Years. Chest, 158(2), 612–619. https://doi.org/10.1016/j.chest.2020.03.069 Vulliamy, T., Marrone, A., Szydlo, R. et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 36, 447–449 (2004). https://doi.org/10.1038/ng1346 Connect With DNA Today Get ready, genetic nerds—another brand-new episode of DNA Today drops this Friday! You can always count on us to deliver fresh content every Friday.  While you wait, why not dive into our library of over 350 episodes? Binge them all on Apple Podcasts, Spotify, our website, or wherever you love to listen—just search “DNA Today.” Prefer watching? We’ve got you covered! For the past four years, we’ve been recording episodes with video, including some filmed at the iconic NBC Universal Stamford Studios. Check them out on our YouTube channel!  DNA Today is hosted and produced by Kira Dineen, MS, LCGC, CG(ASCP)CM . Our Video Lead is Amanda Andreoli. Our Social Media Lead is Liv Davidson. And our logo Graphic Designer is Ashlyn Enokian, MS, CGC.  See what else we are up to on Instagram, X (Twitter), BluSky, Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. Questions/inquiries can be sent to [email protected]
    --------  
    18:56
  • #352 Why Biotech Will Define the 21st Century
    In this bold and wide-ranging conversation, Ian Wendt and Na-Ri Oh sit down with Andrew Craig—British investor, entrepreneur, and author—to explore how biotechnology is poised to shape the next century in the same way physics and computing shaped the last.   Craig draws on his decades of experience as a London and New York investment banker and as a former partner at WG Partners, where he advised more than 60 biotech companies and worked on marquee deals like the $7.6B sale of Nordia Bank and IPOs for brands like EasyJet and Burberry.   But his latest passion lies at the intersection of finance and innovation: making the case that our future is biotech, without a question mark.   This episode originally aired on RealPharma, which is one of 10 shows in our new science podcast network, Gene Pool Media. Thanks to everyone who has supported the network by following us @GenePoolMedia on social. Shoutout to the podcasts in our network, you should check them out! RealPharma Beyond The Thesis with Papa PhD DNA Dialogues It Happened To Me #ThroughTheGenes Demystifying Genetics PhenoTips Speaker Series  All Access DNA Parálisis Cerebral Respuestas Two brand new shows debuting later this year  If you have a science podcast and are interested in joining the network, go to GenePoolMedia.com and click the “Apply” tab at the top right. Or just email me directly at [email protected]. I’d love to chat with you about the benefits of joining the network. Here and there we have been sharing episodes from other podcasts in the Gene Pool Media network.   Topics Covered   Why biology will define the 21st century: Andrew outlines the structural and technological reasons biotech is primed for exponential impact. CRISPR, AI, and the "exponential stack": How data storage, ML, and sequencing speed make today's breakthroughs possible. Fixing Europe's biotech lag: The cultural, capital, and regulatory headwinds slowing biotech innovation in the UK and EU. Rebuilding trust in pharma: Why good actors in drug development don’t get headlines—and how that hurts innovation. From Oxford Biomedica to DNA-based storage: Vivid examples of tech cost reductions and where we're headed next. The case for optimism: How to resist the press's negative bias and invest in human progress—literally. Resources & Links 📘 Andrew’s latest book: Our Future is Biotech on Amazon 📕 His first bestseller: How to Own the World on Amazon 🌐 Plain English Finance: www.plainenglishfinance.com 🔗 Connect with Andrew on LinkedIn: linkedin.com/in/andrewcraigpef Memorable Quotes “The last century was about physics and tech. The next one will be about biology—and by extension, biotech.” “If success begets success, then a crop of billion-dollar biotech companies in Europe can kickstart a self-sustaining cycle of innovation and investment.” “People forget that the smartphone they hold was a $100 million science project in the 1990s. Biotech is heading the same direction.” “We need to fight the narrative that pharma is inherently bad. There are good actors, and we must do a better job telling those stories.” Key Takeaway Biotech isn't just a sector—it's a structural solution to some of humanity’s greatest problems. From disease treatment to environmental restoration, the converging forces of AI, genetics, and biological engineering make this the most consequential time in science since the industrial revolution. Connect With Us Get ready, genetic nerds—another brand-new episode of DNA Today drops this Friday! You can always count on us to deliver fresh content every Friday.  While you wait, why not dive into our library of over 350 episodes? Binge them all on Apple Podcasts, Spotify, our website, or wherever you love to listen—just search “DNA Today.” Prefer watching? We’ve got you covered! For the past four years, we’ve been recording episodes with video, including some filmed at the iconic NBC Universal Stamford Studios. Check them out on our YouTube channel!  DNA Today is hosted and produced by Kira Dineen, MS, LCGC, CG(ASCP)CM . Our Video Lead is Amanda Andreoli. Our Social Media Lead is Liv Davidson. And our logo Graphic Designer is Ashlyn Enokian, MS, CGC.  See what else we are up to on Instagram, X (Twitter), BluSky, Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. Questions/inquiries can be sent to [email protected]
    --------  
    1:03:31

Más podcasts de Educación

Acerca de DNA Today: A Genetics Podcast

Discover New Advances in the world of genetics, from technology like CRISPR to rare diseases to new research. For over a decade, multi-award winning podcast ”DNA Today” has brought you the voices of leaders in genetics. Host Kira Dineen brings her genetics expertise to interview geneticists, genetic counselors, patient advocates, biotech leaders, researchers, and more. ***Best 2020, 2021, and 2022 Science and Medicine Podcast Award Winner*** Learn more (and stream all 350+ episodes) at DNAtoday.com. You can contact the show at [email protected].
Sitio web del podcast

Escucha DNA Today: A Genetics Podcast, kaizen con Jaime Rodríguez de Santiago y muchos más podcasts de todo el mundo con la aplicación de radio.es

Descarga la app gratuita: radio.es

  • Añadir radios y podcasts a favoritos
  • Transmisión por Wi-Fi y Bluetooth
  • Carplay & Android Auto compatible
  • Muchas otras funciones de la app

DNA Today: A Genetics Podcast: Podcasts del grupo

Aplicaciones
Redes sociales
v7.23.3 | © 2007-2025 radio.de GmbH
Generated: 8/31/2025 - 12:10:53 PM